Merck did have its checkbook handy last year. The company acquired Idenix and its hepatitis C drug to speed up development of products to compete with market leader Gilead Sciences Inc. (NASDAQ: GILD). The $3.85 billion price tag caused the shares to fall nearly as much in April as they did in December.